Association between Germline Single-Nucleotide Variants in ADME Genes and Major Molecular Response to Imatinib in Chronic Myeloid Leukemia Patients

Imatinib is the most common first-line tyrosine kinase inhibitor (TKI) used to treat chronic-phase chronic myeloid leukemia (CP-CML). However, only a proportion of patients achieve major molecular response (MMR), so there is a need to find biological factors that aid the selection of the optimal the...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Journal of clinical medicine 2022-10, Vol.11 (20), p.6217
Hauptverfasser:	Estrada, Natalia, Zamora, Lurdes, Ferrer-Marín, Francisca, Palomo, Laura, García, Olga, Vélez, Patricia, De la Fuente, Iris, Sagüés, Miguel, Cabezón, Marta, Cortés, Montserrat, Vallansot, Rolando Omar, Senín-Magán, María Alicia, Boqué, Concepción, Xicoy, Blanca
Format:	Artikel
Sprache:	eng
Schlagworte:	Bone marrow Clinical medicine Drug dosages Genes Inhibitor drugs Kinases Leukemia Metabolism Mutation Patients Polypeptides Targeted cancer therapy
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!